PERAMPANEL | A209538 | TARO PHARMACEUTICAL INDUSTRIES LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Eisai Inc. - Citizen Petition FDA-2013-P-0884 · 4 docket documents Eisai Inc. filed this citizen petition under 21 USC 355(c) and (j) and related provisions requesting that the FDA ensure Eisai receives the full five-year statutory exclusivity period for its two New Chemical Entity products, BELVIQ (lorcaserin hydrochloride) and FYCOMPAT (perampanel). Eisai argues | Other | 2013-08-09 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$20.18
per ea
Lowest NADAC/Unit
$9.09
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 51672420906PERAMPANEL 12 MG TABLET | $20.18 | EA | Generic | — | 2026-06-17 |
| 51672420806PERAMPANEL 10 MG TABLET | $19.84 | EA | Generic | — | 2026-06-17 |
| 51672420706PERAMPANEL 8 MG TABLET | $18.93 | EA | Generic | — | 2026-06-17 |
| 51672420506PERAMPANEL 4 MG TABLET | $16.68 | EA | Generic | — | 2026-06-17 |
| 51672420606PERAMPANEL 6 MG TABLET | $16.22 | EA | Generic | — | 2026-06-17 |
| 51672420406PERAMPANEL 2 MG TABLET | $9.09 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.